Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment

ConclusionThe long -term treatment with onabotulinumtoxinA proved effective, safe and well tolerated over three years. Our findings support the strategy to consistently deliver sessions of use of onabotulinumtoxin Α over long time in CM patients (Trial registration NTC03606356, registered retrospectively, 28 July 2018).

http://link.springer.com/10.1186/s10194-018-0918-3

Source: The Journal of Headache and Pain - September 17, 2018 Category: Neurology Source Type: research